AbCellera Biologics, Inc. (ABCL)

In the past six months, AbCellera reported Q3 2025 earnings with a net loss of $57.1 million and revenue of $9.0 million, and appointed Sarah Noonberg as Chief Medical Officer. AbCellera and Bruker reached a global settlement of patent litigation, including a $35 million upfront payment to AbCellera in Q4 2025. The company reported full-year 2025 revenue of $75.1 million and a net loss of $146.4 million, with ABCL635 advancing into Phase 2 and ABCL575 progressing through Phase 1, leading to a stock rally. Analyst ratings changed, with Leerink Partners downgrading ABCL to 'Market Perform', Wall Street Zen raising shares to a 'hold' rating, and JonesTrading initiating coverage with a 'Strong Buy' rating. The advancement of ABCL635 into Phase 2 and insider buying by CEO Carl Hansen also positively impacted the stock.

Direct demand seasonality is not a significant factor for AbCellera Biologics, Inc. Its revenue is primarily driven by partnerships, research fees, milestone payments, and potential royalties, tied to scientific progress and strategic objectives rather than seasonal consumer purchasing patterns. The company aims to introduce two new molecules into the clinic annually, indicating a continuous development cycle.

AbCellera Biologics, Inc. is a clinical-stage biotechnology company based in Vancouver, British Columbia, specializing in antibody therapeutics discovery and development, operating within the Pharmaceuticals & Biotech, Healthcare, and Biotechnology & Life Sciences sectors. AbCellera utilizes an AI-powered antibody discovery platform to identify antibodies for drug development. Its major products and pipeline programs include ABCL635 for vasomotor symptoms, ABCL575 for atopic dermatitis, ABCL688 for autoimmune disease, ABCL386 for oncology, and COVID-19 treatments developed in collaboration with Eli Lilly and Company.

AbCellera Biologics Inc.'s corporate headquarters are located in Vancouver, British Columbia, Canada. The company also has a global presence through its subsidiaries, which include AbCellera Australia Pty Ltd in Australia, AbCellera Biologics UK Ltd in the United Kingdom, and AbCellera Boston, Inc. in New York, and AbCellera US, Inc. in Delaware, in the United States.

AbCellera's brand reputation has been influenced by its scientific advancements and external challenges. The company benefits from a perception of an "AI premium" and its transition to a clinical-stage biotechnology company. However, a patent infringement lawsuit, scam attempts using the company's name, and scrutiny of its financial performance have impacted its reputation. AbCellera has established a "Business Conduct Reporting" system for individuals to raise concerns.

AbCellera Biologics Inc. is owned by a mix of institutional shareholders (35.76%), insiders (44.36%), and retail investors (19.88%). Major institutional owners include Baker Bros. Advisors Lp, Capital World Investors, and UBS Asset Management Americas Inc. The largest individual shareholder is Carl L. G. Hansen, who owns 18.80% of the company.